Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 16/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6298721 | 0.89 | CCR5 (0.60) | CCR5KCNH2 | |
| SCHEMBL6701710 | 0.86 | CCR5 (0.66) | CCR5KCNH2 | |
| SCHEMBL6705240 | 0.82 | KCNH2 (0.62) | CCR5OPRM1TMEM97KCNH2 | |
| SCHEMBL7084347 | 0.81 | HTR2A (0.61) | CCR5MEN1KMT2AHTR2ACYP2D6 | |
| SCHEMBL7603229 | 0.81 | MEN1 (0.63) | CCR5MEN1KMT2AHTR2ACYP2D6 | |
| SCHEMBL6755242 | 0.77 | CCR5 (0.61) | CCR5CHRM1HTR2AKCNH2 | |
| SCHEMBL9994976 | 0.76 | OPRM1 (0.71) | CCR5OPRM1TMEM97 | |
| SCHEMBL7601798 | 0.75 | L3MBTL1 (0.64) | CCR5OPRM1MEN1KMT2ACHRM1 | |
| SCHEMBL4164384 | 0.75 | MEN1 (0.56) | CCR5MEN1KMT2AHTR2ACYP2D6 | |
| SCHEMBL341871 | 0.75 | OPRM1 (0.66) | CCR5OPRM1TMEM97HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110794-A1 | Novel piperidine derivatives as modulators of chemokine receptors | ASTRAZENECA AB (SE) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110794-A1 | Novel piperidine derivatives as modulators of chemokine receptors | CCR5, CCR2, CXCR1 | CCR5 1/4885OPRM1 33/4885TMEM97 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.